A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)

LMI’s tasks/obkectives  LMI should be the obvious association (choice) both for the multinational companies and the smaller Norwegian entrepreneurs operating in the pharmaceutical / life science area  The associations objective is to protect the member companies’ interests related to

LMI in brief  52 members per December 1st 2012  More than 80 % of the total pharmaceutical sales  Member companies employ about people  Cooperation and dialogue partner for the authorities  Liaison between industry and authorities

Drug sales in Norway 2012  18.6 billion (PRP)  An increase of 0.3 in the PRP  12 billion (AIP)  Growth of 1.4 percent in the DDD  9.1 billion in reimbursement  71 percent of expenditures financed by the public  25 percent VAT on all medicines  Low rates  Drug consumption is below average in the Nordic countries

Organisation of the LMI Group  LMIs management is funded by the members through a service charge  Shareholders, board and management  14 committees, where employees of member firms contribute  Felleskatalogen AS and Farmastat AS are independent subsidiaries  The industry has 12 employees, Felleskatalogen has 5 and Farmastat has 6 employees

Vision and goal Vision  Medical advances for better health Objectives / goals  Greater visibility and a good and trusting relationship with the outside world  Ensure that the Norwegian patients get quick access to medical innovations  Increase research, production and business development at pharmaceutical area in Norway  Ensuring a good framework for the industry

Our business areas  Visibility / communications  Policy work / conditions  Organization  Member Services

Wealth creation and visibility (1)  LMI would like to take a new and clear role as a political influence, and contribute to a stronger visibility of the pharmaceutical industry's contribution to society.  LMI will be a future-oriented trade organization that promotes business and health policy views on behalf of the member-companies. In addition to protect industry interests, LMI will maintain a strong focus on the patient and the patients' rights.

Wealth creation and visibility (2)  There is a need for increased activity and efforts related to the promotion of research and industrial development in the pharmaceutical area in Norway, and a greater extent assure needs of small, established Norwegian companies.  LMI will maintain a membership service of high quality.

Working methods  Visibility  Professional expertise and credibility  Dialogue and cooperation rather than conflict  Participation in broader health policy arenas  Networking  Dialogue with alliance partners

Transparency and tidiness  Clear and binding framework for cooperation through agreements (RHF DNLF, NFF, NSF, FFO)  Updated internal and self-imposed rules (Rules for drug information)  Industry internal awareness in relation to ethical issues  The principle is that all interactions should be open, verifiable, and withstand a critical light

What expertise do LMI have?  Research and development - clinical trials  Approval of drugs / regulatory affairs  Price, reimbursement and revenue  Health Economics – Statistics  Drug Policy / Health Policy  Rules and regulations for marketing  Industry Information  Information - Press & Media  Public Affairs  Member Services and courses

Working methods